Randomized controlled trialHumanClinical Trial, Phase II
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Lancet (London, England), 2023 Aug 12. Rosenstock J, Frias J, Jastreboff AM and 8 others.
Study type
Randomized controlled trial · Clinical Trial, Phase II
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Lancet (London, England)
Published
2023 Aug 12
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultFemaleHumansMaleMiddle AgedBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodGlucagonGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptides
Other papers on Retatrutide
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page